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In the work described here, the effect of intranasal immunization of BALB/c mice with synthetic chimeric peptides
consisting of a cytotoxic T-cell epitope (amino acids 81–95) from the M2 protein of respiratory syncytial virus (RSV) and a
fusion peptide (amino acids 113–131) from the F1 protein of measles virus on response to challenge with RSV has been
assessed. Three intranasal immunizations with the chimeric peptides without adjuvant induce peptide- and RSV-specific
cytotoxic T-cell responses (CTL) at 1 or 3 weeks after the third immunization. The CTL responses significantly declined at 6
weeks after immunization. Furthermore, viral load in the lungs following challenge with RSV was significantly reduced in mice
immunized with the F/M2:81-95 chimeric peptide compared to control animals at 1 or 3 weeks after immunization and no
reduction of RSV titers was detectable 6 weeks after immunization. The CTL activity induced by F/M2:81-95 was therefore
short-lived (less than 6 weeks) but was significantly correlated with the reduction in viral load in the lungs. © 1998 Academic
Press
INTRODUCTION
Respiratory syncytial virus (RSV) is a major lower re-
spiratory tract pathogen in infants and young children
worldwide, resulting in approximately 91,000 hospitaliza-
tions and 4500 deaths yearly in the United States alone
(1). The severity and frequent occurrence of the disease
in infants under 6 months of age has prompted the WHO
to select RSV as a high priority for vaccine development.
Previous trials with live attenuated and killed vaccines
have been unsuccessful and indeed, a formalin-inacti-
vated vaccine preparation induced more severe disease
when vaccinees became infected during a subsequent
RSV outbreak (2, 3). Since the inactivated RSV vaccine
was not formulated in a way specifically to induce MHC
class I-restricted responses, it is unlikely that CD81
cytotoxic-lymphocytes (CTL) play a major role in the
vaccine-enhanced illness observed following subse-
quent RSV infection (4). However, passive transfer of 106
RSV-specific cytotoxic T lymphocytes (CTL) cleared virus
from the lungs of infected mice (5) but the transfer of
higher doses of RSV-specific CTL induced hemorrhagic
pneumonia and illness (6). Therefore, it is not clear if, for
the development of a successful vaccine, it will be im-
portant to include elements to stimulate CTL responses
(7). Resistance to RSV infection in BALB/c (H-2d) mice
following immunization with a vaccinia recombinant ex-
pressing the M2 protein of the virus has been shown to
be mediated by a single H-2d-restricted determinant (M2:
82-90) (8). The fusion (F) protein of paramyxoviruses is a
type 1 integral membrane protein involved in virus pen-
etration, hemolysis, and cell fusion (9) which is synthe-
sized as an inactive precursor (Fo). This is cleaved by a
host cell proteolytic enzyme to form the biologically ac-
tive protein consisting of the disulphide linked chains F1
and F2, resulting in the release of the N-terminus of F1,
the N-terminal 19 residues of which (fusion peptide) are
extensively hydrophobic and conserved among para-
myxovirus F proteins (10).
Using microspectrofluorometry, we have previously
demonstrated that the attachment of this peptide to the
M2 CTL epitope results in the binding of the chimeric
peptide to the cell membrane, its internalization into the
cytosol and processing and presentation of the CTL
epitope via the class I pathway (11). Furthermore, we
have also shown that a chimeric synthetic peptide rep-
resenting residues 81–95 of the M2 protein linked to the
fusion peptide of measles virus does indeed efficiently
prime RSV-specific CTLs in vivo following systemic im-
munization without adjuvant (12). In the work described
here, we tested the ability of this synthetic peptide to
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induce long-lasting CTL responses and the duration of
resistance to RSV challenge induced following mucosal
immunization via the intranasal route.
RESULTS AND DISCUSSION
The F/M2:81-95 peptide induced systemic CTL re-
sponses following intranasal immunization without adju-
vant, whereas M2:81-95/F induced lower CTL responses
and M2:81-95 alone was not immunogenic (Fig. 1). Re-
peated intranasal immunization with F/M2:81-95 without
adjuvant was required to generate detectable CTL activ-
ity (Fig. 2). Peptide- and virus-specific CTL responses
significantly declined at 6 weeks after three intranasal
immunization with F/M2:81-95 without adjuvant com-
pared to those observed at 1 and 3 weeks after immu-
nization (Fig. 3). However, there was no detectable anti-
F/M2:81-95 peptide or anti-RSV antibody in these mice.
Mice previously immunized i.n. three times with F/M2:
81-95 exhibited a significant reduction of RSV titer in the
lungs compared to the controls 1 week after final immu-
nization (1.06 log10 fold reduction in titer, P 5 0.016).
Furthermore, the number of RSV-infected cells in lung
washes was significantly reduced in the group immu-
nized with F/M2:81-95 (P 5 0.008). It is important to note
that two of the five mice had no detectable virus-infected
lung wash cells. A significant reduction of viral load was
still observed 3 weeks after the final immunization but
was not detectable 6 weeks later. The presence of CTL
activity was significantly correlated with the duration of
resistance to RSV challenge following intranasal immu-
nization with F/M2:81-95 without adjuvant (Table 1).
There is a significant difference in the epitope-specific
CTL responses elicited by two chimeric peptides with
two orientations (Fig. 1). The F/M2:81-95 peptide has
been shown to adopt an alpha-helical structure in a
hydrophobic environment and is able to bind to the cell
membrane. On the other hand, the M2:81-95/F peptide
adopts a beta sheet structure in the same environment
and is unable to insert into the cell membrane (11). These
differences may thus account for the more efficient in-
duction of CTL responses by the F/M2:81-95 peptide
which would result from its more effective internalization
into the cytosol and presentation via the class I pathway.
The resistance to RSV infection by primary CTLs in-
duced in mice by immunization with recombinant vac-
cinia expressing the M2 protein or mutant fusion protein
is short-lived (16, 17). Mice immunized by the i.n. or i.p.
routes with these recombinants developed significant
resistance to RSV infection after 9 days and this resis-
tance disappeared 28 days after immunization. Resis-
tance to RSV was also induced following immunization of
mice with a vaccinia recombinant expressing a minigene
representing residues 82-90 of the M2 protein of RSV (8).
In the work presented here, we have confirmed and
extended these observations and have demonstrated
that intranasal immunization with F/M2:81-95 without ad-
FIG. 1. Induction of peptide- and virus-specific CTL activity following i.n. immunization three times with 10 nmol F/M2:81-95, M2:81-95/F, M2:81-95,
and saline at 7-day intervals. (A) Peptide-specific CTL activity was measured with P815 target cells pulsed with 5 mM of M2:82-90. (B) Virus-specific
CTL activity was measured with P815 target cells infected with RSV at 10 PFU/cell. The lysis of P815 control cells was less than 5%. Four mice were
used in each group. The results presented are representative of three separate experiments.
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juvant can also reduce the RSV titer in the lungs. Al-
though there appeared to be a greater reduction in the
number of infected lung wash cells (50-fold) than the
reduction in RSV titer in the lungs (18-fold), the results
were closely correlated. It is very likely that the immu-
nofluorescence method for detection of virus infection is
less sensitive than the titration of virus in the lungs.
Although a single parenteral immunization with F/M2:
81-95 with adjuvant has been shown to be sufficient to
induce CTL responses in vivo (12), repeated intranasal
immunization seems to be critical for CTL priming by
synthetic peptide in the absence of adjuvant (Fig. 2). The
limited reduction in virus titer observed may be because
the frequency or avidity of CTLs induced by F/M2:81-95
was not sufficient for virus clearance in vivo (18). Al-
though recombinant vaccinia virus vaccines are able to
protect RSV infection in vivo, such vaccines are unlikely
to be used in human beings, particularly because of the
potential problems of immunocompromised patients,
older individuals, or infants.
Previous reports have suggested that primary CTLs
are more effective in restricting the replication of chal-
lenge RSV than are memory CTLs (16). The results pre-
sented here raise the important question of the induction
of memory CTL by intranasal immunization with the syn-
thetic peptide. Transfer of high does of RSV-specific
CTLs cleared virus but induced enhanced illness (6). In
our experiments, there was no demonstrable enhance-
ment of pathology in F/M2:81-95 immunized mice (data
not shown). It has been reported that the long-term
memory virus-specific CTL responses are induced fol-
lowing infection with live virus and memory CTL re-
sponses are maintained without persistent presence of
antigens in vivo (19, 20). However, the microenvironment
and signals that maintain the memory of protective CTL
responses are still not clear. It has been suggested that
CD41 T-cells (21) and certain costimulatory molecules,
such as B-7 and H5A (22), are important at inducing and
maintaining long-lived CTL responses. Currently, there
are no data regarding the duration of CTL responses
induced by synthetic peptides. In our experiments, pep-
tide- and virus-specific CTL activities were observed at 1
and 3 weeks but were not significant 6 weeks after three
intranasal immunizations with the F/M:81-95 peptide
without adjuvant. The reason that F/M2:81-95 peptide
cannot induce long-lived protective CTL responses may
be due to insufficient CD41 T-cell activity or lack of
signals from costimulatory molecules.
In conclusion, we have demonstrated that intranasal
immunization with a chimeric synthetic peptide without
the use of an adjuvant induces a CTL response which is
associated with a significant reduction in RSV titer in the
lungs of infected mice. The addition of T helper epitopes
into the peptide vaccine constructs may increase the
efficacy of a peptide vaccine at inducing long-lasting
protective immunity. Alternatively, the coexpression of
minigenes expressing CTL epitopes with genes encod-
ing costimulatory molecules or cytokines in plasmid DNA
FIG. 2. Induction of peptide- and virus-specific CTL activity following i.n. immunization once (A) or three times (B) with 10 nmol F/M2:81-95 in saline
at 7-day intervals. Peptide-specific CTL activity was measured with P815 target cells pulsed with 5mM of M2:82-90. Virus-specific CTL activity was
measured with BCH4 cells (BALB/c fibroblasts persistently infected with RSV).
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FIG. 3. Induction of peptide- and virus-specific CTL activity at (A) 1, (B) 3, and (C) 6 weeks after i.n. immunization three times with 10 nmol of
F/M2:81-95 at 7-day intervals. Peptide-specific CTL activity was measured with P815 target cells pulsed with 5 mM of M2:82-90. Virus-specific CTL
activity was measured with BCH4 cells (BALB/c fibroblasts persistently infected with RSV).
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vaccines may represent an efficient way of inducing
long-term protective immune responses to different
pathogens.
MATERIALS AND METHODS
Peptide synthesis
Two peptides representing a previously defined CTL
epitope from the M2 protein of RSV (M2:82-90 and M2:
81-95) and two chimeric peptides representing residues
81–95 and residues 113–131 from the fusion peptide (F)
of measles virus (M2:81-95/F and F/M2:81-95) were syn-
thesized by automated solid phase synthesis (9050 Pep
synthesiser, Division of Millipore, Milligen, Bedford, MA)
using Fmoc-chemistry with the f-[29, 49-dimethyloxy phe-
nyl-Fmoc-amino-methyl)-phenoxy] resin (Novabiochem,
Nottingham, UK) (Table 2).
Virus and cells
The A2 strain of RSV grown and titrated in HEp-2 cell
monolayer cultures as previously described (13) was
used for infection and for the assay of cytotoxic T cells.
Immunization and CTL assays
Six-week-old female BALB/c mice (H-2d) were anes-
thetized with halothane and were then immunized intra-
nasally (i.n.) with 10 nmol of F/M2:81-95, M2:81-95/F, and
M2:81-95 in 30 ml saline once or three times at 1-week
intervals. One, 3, or 6 weeks after the final immunization,
spleen cells were harvested and restimulated in vitro
with 0.5 mM M2:82-90 in 10% ConA supernatant-contain-
ing medium (RPMI-1640 medium containing 10% fetal
calf serum, 2 mM L-glutamine, 10 mg/ml penicillin, 10
mg/ml streptomycin, and 5 3 1025 M 2-mercaptoetha-
nol). After 7 days, CTL activity in the spleen cells was
assessed using M2:82-90-pulsed P815 cells, RSV-in-
fected P815 cells, and BCH4 cells (BALB/c fibroblasts
persistently infected with RSV) (14) as targets.
RSV challenge experiments
To assess the effectiveness of peptide-specific CTL
against challenge with RSV, groups of mice were anes-
thetized with halothane and were then intranasally im-
munized with either the F/M2:81-95 chimeric peptide, a
mixture of fusion peptide and M2:81-95 (F1M2:81-95), or
with 30 ml saline alone three times once a week for 3
weeks. All mice were challenged with 106 PFU/50ml RSV
at 1, 3, or 6 weeks after final immunization. As a positive
control for protection, a separate group of mice was
infected i.n. with RSV (106 PFU/50 ml) 9 days before the
challenge. Four days following challenge (the time of
peak virus titer (15)), the mice were killed, lung wash
cells collected, and RSV-infected cells enumerated by
immunofluorescence staining. Lung wash cells were
spun at 400 g for 10 min and resuspended in PBS (200
ml). The total number of cells obtained ranged from 3 3
TABLE 2
Notation and Sequences of Peptides Used
Notation Sequence
M2:82–90 SYIGSINNI
M2:81–95 ESYIGSINNITKQSA
F FAGVVLAGAALGVAAAAQI
F/M2:81–95 FAGVVLAGAALGVAAAAQIESYIGSINNITKQSA
M2:81–95/F ESYIGSINNITKQSAFAGVVLAGAALGVAAAAQI
TABLE 1
Ability of Different Peptide Vaccines to Reduce RSV Infection in Lung and Lung Wash Cells
Mice immunized with a
RSV titer in the lung
(log10 p.f.u./gram)
b
Number of RSV infected cells/
103 lung wash cellsc
Mice with detectable RSV
infected lung wash cells
F/M2:81–95 (6 weeks) 4.06 6 0.22 (P . 0.1)d ND ND
F/M2:81–95 (3 weeks) 3.64 6 0.25 (P 5 0.0159)d ND ND
F/M2:81–95 (1 week) 3.27 6 0.31 (P 5 0.0159)d 0.278 6 0.161 (P 5 0.008)d 3/5
F1M2:81–95 (1 week) 4.52 6 0.17 (P . 0.05)d 5.48 6 3.077 (P . 0.1)d 5/5
Saline 4.33 6 0.17 13.75 6 7.029 5/5
RSV , 2.1 ND ND
Note. ND, not determined.
a Mice were immunized with different peptide vaccines three times at 7-day intervals and were challenged with RSV (106 PFU/50 ml) at 1, 3, or 6
weeks after final immunization. Animals in the RSV group received RSV (106 PFU) on day 0 and were challenged i.n. with RSV (106 PFU/50 ml) on day
9 as controls. Lungs were removed and lung washes were performed 4 days later for quantification of virus titers.
b Four to five animals/group were analyzed: Values represent mean log10 RSV titer 6 standard deviation. The lowest level of virus detectable in this
assay was log10 2.1 PFU/gram of lung tissue.
c Five animals/group were analyzed: Values represent mean 6 standard deviation of the number of RSV infected cells in 103 lung wash cells. The
number of RSV infected lung wash cells was determined by direct immunofluorescence. The total number of lung wash cells analyzed in this assay
ranged between 7.5 3 104 and 15 3 104.
d The significance of the differences in reduction of RSV titer in the lungs and the number of RSV infected cells in lung washes were analyzed in
comparison to the saline control group (Mann–Whitney test).
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106 to 6 3 106 cells/ml. Of the resuspended cell suspen-
sion, 25 ml was placed into a 6-mm-well area of a Teflon
coated microscopic slide, air-dried, and fixed with ace-
tone for 10 min at room temperature. RSV-infected cells
were detected by incubating a mixture of FITC-labeled
monoclonal anti-RSV antibodies (Imagen RSV, Dako,
Glostrup, Denmark) for 15 min at 37°C. Finally, the slides
were extensively washed, dried and mounted and the
number of RSV-infected cells were counted and ex-
pressed per 103 total wash cells.
For viral titration, lungs from four to five mice in each
group were harvested and homogenized in sterile stabi-
lizing buffer with a glass tissue grinder. The homoge-
nates were centrifuged at 10,000 g for 1 min and the
supernatants assayed immediately or stored in liquid
nitrogen. Stabilizing buffer comprised 95 ml of Hank’s
balanced salt solution (Gibco) containing 2.5 ml sodium
bicarbonate (5.6%), 2.5 ml Hepes (1 M), 200 U penicillin/
streptomycin, 0.22 M sucrose, 4.8 mM glutamate, and 30
mM magnesium chloride and was sterilized through a
0.22-mm filter (Gelman Acrodisc), prior to freezing in 10
ml aliquots at 220°C. The titer of RSV was estimated
using a plaque assay as previously described and is
expressed as log10 titer/g lung tissue (13).
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